Skip to content

Study · Animal study (in vivo) · rat · 2012

4 results

Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)).

Watanabe A, Yoneyama S, Nakajima M, Sato N, Takao-Kawabata R, Isogai Y, Sakurai-Tanikawa A, Higuchi K, Shimoi A, Yamatoya H, Yoshida K, Kohira T

The Journal of toxicological sciences1 Jan 2012Cited by 61 (Europe PMC)

PMID22688001 (opens in a new tab)DOI10.2131/jts.37.617 (opens in a new tab)PepBankPUB-22688001
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In male and female Sprague-Dawley rats, daily teriparatide increased osteosarcoma incidence at the reported dose.

    In plain wordsIn rats, daily teriparatide increased bone cancer incidence at the reported dose.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOsteosarcoma incidence
    Study

    ratsn: not reported in source

    Sprague-Dawley rats
    Outcome group
    Adverse events · Cancer
    Studied dose
    13.6 µg/kg/day · subcutaneous · 2 yearsAs given in this study (rats).

    Source sentences

    Summary
    When teriparatide was administered subcutaneously to male and female Sprague-Dawley (SD) rats daily for 2 years, the incidence of osteosarcoma was increased at 13.6 µg/kg/day.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In male and female Sprague-Dawley rats, the non-carcinogenic teriparatide dose level was 4.5 µg/kg/day.

    In plain wordsIn rats, the reported non-carcinogenic teriparatide dose was 4.5 µg/kg/day.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableNon-carcinogenic dose level
    Study

    ratsn: not reported in source

    Sprague-Dawley rats
    Outcome group
    Adverse events · Cancer
    Studied dose
    4.5 µg/kg/day · subcutaneous · 2 yearsAs given in this study (rats).

    Measurements

    Non-carcinogenic dose
    4.5 µg/kg/day
    male and female rats

    Source sentences

    Summary
    The non-carcinogenic dose level was 4.5 µg/kg/day for both males and females.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In Sprague-Dawley rats, osteosarcoma development depended on teriparatide dose and treatment duration.

    In plain wordsIn rats, bone cancer development depended on teriparatide dose and treatment duration.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableDose and duration dependence of osteosarcoma
    Study

    ratsn: not reported in source

    Sprague-Dawley rats
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated · subcutaneous · 2 yearsAs given in this study (rats).

    Source sentences

    Summary
    The development of osteosarcoma in SD rats depends on the dose level of, and treatment duration with, teriparatide.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 04AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Activity measurement

    In rats, bone responses to teriparatide were similar in many aspects between Sprague-Dawley and F344 strains.

    In plain wordsIn rats, many bone responses to teriparatide were similar between the two strains.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableBone response across rat strains
    Study

    ratsn: not reported in source

    Sprague-Dawley rats
    Comparator
    F344 rats
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Responses of the bones to teriparatide were similar between F344 and SD rats in many aspects.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.